Sugi Predict

Sugi Predict / Compounds / SCHEMBL17337458

SCHEMBL17337458

SCHEMBL17337458

CNS(=O)(=O)CCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APEX1 P27695 2/20 0.52
▸ KDM4E B2RXH2 3/20 0.39
▸ EGLN1 Q9GZT9 3/20 0.39
▸ KDM5C P41229 2/20 0.39
▸ PHF8 Q9UPP1 2/20 0.39
▸ KDM2A Q9Y2K7 2/20 0.39
▸ LMNA P02545 3/20 0.38
▸ ALKBH5 Q6P6C2 1/20 0.38
▸ SUCNR1 Q9BXA5 1/20 0.38
▸ FFAR3 O14843 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ KMT2A Q03164 1/20 0.37
▸ HTT P42858 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SLC15A2 Q16348 1/20 0.36
▸ KDM6B O15054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25380148 0.98 APEX1 (0.50) APEX1KDM4EEGLN1KDM5CPHF8
SCHEMBL26650508 0.86 LMNA (0.43) APEX1LMNAKMT2AALDH1A1SLC22A6
SCHEMBL1654402 0.84 LMNA (0.48) LMNAKMT2AALDH1A1SLC22A6TSHR
SCHEMBL21423959 0.78 LMNA (0.44) LMNA
SCHEMBL12916982 0.78 ALDH1A1 (0.33) LMNAALDH1A1
SCHEMBL22092733 0.78 ALOX15 (0.33) APEX1
SCHEMBL25827382 0.76 TSHR (0.52) KDM4ELMNAKMT2AHTTALDH1A1
SCHEMBL27872399 0.75 APEX1 (0.52) APEX1KDM4EEGLN1KDM5CPHF8
SCHEMBL19919844 0.75 — —
SCHEMBL4922033 0.74 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3882252-B1 BETA-LACTAMASE INHIBITORS VENATORX PHARMACEUTICALS INC (US) 2025-11-19 — — EP disclosed
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 — — EP disclosed
CN-119497712-A Indane derivatives as MALT1 inhibitors 希四克斯探索有限公司 2025-02-21 — — CN disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 — — US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 — — US disclosed
WO-2023218203-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-11-16 — — WO disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 — — US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 — — US disclosed
EP-3882252-A1 BETA-LACTAMASE INHIBITORS Venatorx Pharmaceuticals, Inc. (US) 2021-09-22 — — EP disclosed
US-11008346-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2021-05-18 — — US disclosed
CN-109988186-A Beta-lactamase inhibitor 维纳拓尔斯制药公司 2019-07-09 — — CN disclosed
CN-106687465-B β -lactamase inhibitor 维纳拓尔斯制药公司 2019-04-16 — — CN disclosed
US-9926336-B2 Beta-lactamase inhibitors VENATORX PHARMACEUTICALS (US) 2018-03-27 — — US disclosed
US-20170342092-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-11-30 — — US disclosed
US-9783555-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2017-10-10 — — US disclosed
US-20170226135-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-08-10 — — US disclosed
US-9637504-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2017-05-02 — — US disclosed
EP-3154989-A1 BETA-LACTAMASE INHIBITORS Venatorx Pharmaceuticals, Inc. (US) 2017-04-19 — — EP disclosed
US-20160264598-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-15 — — US disclosed
WO-2015191907-A1 BETA-LACTAMASE INHIBITORS VenatoRx Pharmaceuticals, Inc. (US) 2015-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008346-B2 Beta-lactamase inhibitors MGAM, GAA, LCT APEX1 874/4885KDM4E 720/4885EGLN1 797/4885
US-20170342092-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT APEX1 874/4885KDM4E 720/4885EGLN1 797/4885
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 APEX1 750/4885KDM4E 1163/4885EGLN1 1078/4885
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 APEX1 750/4885KDM4E 1163/4885EGLN1 1078/4885
US-20170226135-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT APEX1 874/4885KDM4E 720/4885EGLN1 797/4885
US-20160264598-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT APEX1 874/4885KDM4E 720/4885EGLN1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.